BrainsWay Ltd. (BWAY) - 2024 Annual Report (Form 20-F) Summary
Business Context and Reporting Period
Company: BrainsWay Ltd.
Reporting Period: Fiscal year ended December 31, 2024.
Business Overview: BrainsWay is a global leader in non-invasive neurostimulation, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology. The company holds FDA clearances for three indications: Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), and smoking addiction. Operations are primarily based in Israel, with significant commercial activities in the United States.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (USD) | 2023 (USD) | Change |
|---|---|---|---|
| Total Revenues | $41.0 million | $31.8 million | +29% |
| Net Income (Loss) | $2.9 million | ($4.2 million) | Turnaround to Profit |
| Operating Profit (Loss) | $1.4 million | ($5.0 million) | Turnaround to Profit |
| Gross Margin | 74.6% | 73.9% | Stable |
| Cash & Equivalents | $69.3 million | $10.5 million | Significant Increase |
| Operating Cash Flow | $10.3 million | $1.3 million | Positive |
| Accumulated Deficit | ($98.4 million) | ($101.3 million) | Reduced |
Note: Revenue breakdown includes $22.4 million from sales, $14.5 million from leases, and $4.1 million from services. The U.S. market accounted for 81% of total revenue.
Material Changes vs. Prior Period
- Profitability: The company achieved its first annual net profit ($2.9 million) and operating profit ($1.4 million) in 2024, reversing a net loss of $4.2 million in 2023. This was driven by a 29% revenue increase and improved cost management.
- Liquidity: Cash and cash equivalents surged to $69.3 million from $10.5 million in 2023. This increase was primarily due to a $20 million private placement of ADSs and warrants to Valor BrainsWay Holdings, LLC in November 2024, and a reclassification of short-term deposits.
- Revenue Mix: Lease revenue grew significantly (from $8.5M to $14.5M), reflecting an expanding installed base of 1,353 systems (up 252 in 2024).
- Geopolitical Impact: The filing highlights disruptions caused by conflicts in the Middle East (Israel-Gaza, Israel-Hezbollah), leading to increased shipping costs, supply chain delays, and the drafting of employees into military reserves.
Guidance, Outlook, and Risks
Outlook: Management believes existing cash resources ($69.6 million including restricted cash and short-term deposits) are sufficient to fund operations for the foreseeable future. The company plans to continue investing in R&D for next-generation "Rotational Field" technology and expanding clinical trials for new indications (e.g., alcohol use disorder, post-stroke rehabilitation).
Key Risks:
- Geopolitical Instability: Ongoing conflicts in Israel pose risks to manufacturing, supply chains, and employee availability (reserve duty).
- Reimbursement: While MDD reimbursement is robust, coverage for OCD is emerging, and smoking addiction currently lacks third-party reimbursement, relying on cash-pay models.
- Competition: Intense competition from traditional TMS competitors (e.g., Neuronetics) and pharmaceutical alternatives (e.g., esketamine, Auvelity).
- Intellectual Property: Reliance on in-licensed patents from the U.S. Public Health Service (PHS) and Yeda Research, with some core patents expiring or expiring soon.
- Regulatory: Risks associated with FDA inspections, off-label use, and potential changes in healthcare policy under new U.S. administrations.
Investor Verification Checklist
- Cash Runway: Verify the sustainability of the $69.3 million cash position against projected R&D and commercialization burn rates.
- Reimbursement Trends: Monitor the expansion of insurance coverage for OCD and any breakthroughs in reimbursement for smoking addiction.
- Supply Chain Resilience: Assess the long-term impact of Middle East conflicts on manufacturing costs and delivery timelines.
- Installed Base Growth: Track the conversion rate of leased systems to sales and the utilization rates of the 1,353 installed systems.
- Patent Expirations: Review the timeline for expiring core patents and the status of new patent filings for next-generation technology.